{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:44:13Z","timestamp":1787316253391,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.bonr.2021.101090","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T23:30:26Z","timestamp":1620343826000},"page":"101090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study"],"prefix":"10.1016","volume":"14","author":[{"given":"Koki","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Toyone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2021.101090_bb0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2021.101090_bb0010","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group","volume":"85","author":"Black","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2021.101090_bb0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2021.101090_bb0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bonr.2021.101090_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bonr.2021.101090_bb0030","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00198-010-1409-9","article-title":"Diffuse idiopathic skeletal hyperostosis (DISH): relation to vertebral fractures and bone density","volume":"22","author":"Diederichs","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2021.101090_bb0035","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00774-017-0861-4","article-title":"Assessment of the effects of switching oral bisphosphonates to denosumab or daily teriparatide in patients with rheumatoid arthritis","volume":"36","author":"Ebina","year":"2018","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bonr.2021.101090_bb0040","first-page":"47","article-title":"The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies","volume":"10","author":"Iolascon","year":"2013","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"10.1016\/j.bonr.2021.101090_bb0045","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2147\/TCRM.S123172","article-title":"High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis","volume":"12","author":"Ishikawa","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bonr.2021.101090_bb0050","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2147\/CIA.S180614","article-title":"High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis","volume":"13","author":"Ishikawa","year":"2018","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.bonr.2021.101090_bb0055","doi-asserted-by":"crossref","first-page":"E473","DOI":"10.1097\/BSD.0000000000000703","article-title":"A novel method for the prediction of the pedicle screw stability: regional bone mineral density around the screw","volume":"31","author":"Ishikawa","year":"2018","journal-title":"Clin. Spine Surg."},{"key":"10.1016\/j.bonr.2021.101090_bb0060","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00198-016-3764-7","article-title":"Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients","volume":"28","author":"Kamimura","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2021.101090_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40634-019-0211-7","article-title":"Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates","volume":"6","author":"Kaneko","year":"2019","journal-title":"J. Exp. Orthop."},{"key":"10.1016\/j.bonr.2021.101090_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12905-020-00913-x","article-title":"Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study","volume":"20","author":"Kobayashi","year":"2020","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.bonr.2021.101090_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jocd.2017.01.005","article-title":"Quadrant analysis of quantitative computed tomography scans of the femoral neck reveals superior region-specific weakness in young and middle-aged men with type 1 diabetes mellitus","volume":"21","author":"Kuroda","year":"2018","journal-title":"J. Clin. Densitom."},{"key":"10.1016\/j.bonr.2021.101090_bb0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00784-014-1309-z","article-title":"Nitrogen-containing bisphosphonates modulate the antigenic profile and inhibit the maturation and biomineralization potential of osteoblast-like cells","volume":"19","author":"Manzano-Moreno","year":"2015","journal-title":"Clin. Oral Investig."},{"key":"10.1016\/j.bonr.2021.101090_bb0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11657-017-0371-y","article-title":"Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis: denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis","volume":"12","author":"Nakamura","year":"2017","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.bonr.2021.101090_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2021.101090_bb0095","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","article-title":"Executive summary of the Japan osteoporosis society guide for the use of bone turnover markers in the diagnosis and treatment of osteoporosis (2018 edition)","volume":"498","author":"Nishizawa","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bonr.2021.101090_bb0100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bone.2011.06.027","article-title":"Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover","volume":"49","author":"Peris","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2021.101090_bb0105","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.bonr.2021.101090_bb0110","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.1543","article-title":"Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo","volume":"27","author":"Roelofs","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2021.101090_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2021.101090_bb0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2021.101090_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2021.101090_bb0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bonr.2021.101090_bb0135","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bonr.2018.03.006","article-title":"Denosumab significantly improves lumbar spine bone mineral density more in treatment-naive than in long-term bisphosphonate-treated patients","volume":"8","author":"Suzuki","year":"2018","journal-title":"Bone Rep."},{"key":"10.1016\/j.bonr.2021.101090_bb0140","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00198-018-4624-4","article-title":"Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling","volume":"29","author":"Winzenrieth","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2021.101090_bb0145","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00774-009-0080-8","article-title":"Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis\/osteoporosis against disability study","volume":"27","author":"Yoshimura","year":"2009","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.bonr.2021.101090_bb0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2021.101090_bb0155","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10928-015-9422-4","article-title":"Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data","volume":"42","author":"Zheng","year":"2015","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187221003466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187221003466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:25:19Z","timestamp":1762446319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187221003466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"alternative-id":["S2352187221003466"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2021.101090","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2021.101090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101090"}}